Our Company
N2MO is operating in the early drug discovery environment where our offerings ensure the research companies faster, cheaper and more flexible processes to detect compounds for further processing towards final drug development.
Through close collaboration with academia in Europe as well as with biotech and big pharma companies we have developed and fine tuned the models so they accommodate the need for science and for commercial drug discovery.
The data have been published in peer reviewed magazines and now we are ready to commercialize the services in large scale.
As CRO service we offer our fully validated ex vivo screening models providing an exciting opportunity to make customized study design generating more sophisticated and completely unique data to assess:
- Barrier permeability that discriminates CNS from non-CNS compounds.
- Concentration dependent brain uptake patterns.
- Identification and classification of Pgp transporter substrates.
- Identification of energy dependent substrate transport.
- Quantification of BBB permeability.
- Pgp substrates that may have terapeutic effect on CNS target.
- Transporter substrates (Influx / efflux).
- Slow vs fast permeating compounds.
Management

With his technical and commercial background Preben has spend almost his whole career in…

Björn has more than 20 years experience within the Life Science sector…
Board of Director

With Karin’s medical and commercial background Karin has spend almost her whole career in international business…

Erik brings along 25 years of international General Management, Board and …

With his scientific back ground Klaus has devoted his career to drug discovery…

Martin is the CFO at Retap and has been working in the financial sector for more than 20 years…

Michael is partner at the law firm Rønne & Lundgren and renowned as one of the leading…

With his technical and commercial background Preben has spend almost his whole career in…